Nanoscope Therapeutics

Executive Summary

Nanoscope Therapeutics is a private, preclinical-stage gene therapy company based in Bedford, Texas, pioneering ambient light-activated optogenetics to restore vision in patients with inherited retinal degenerations, including Retinitis Pigmentosa, Stargardt disease, and dry age-related macular degeneration. The company's technology employs non-viral or viral delivery of light-sensitive proteins to convert remaining inner retinal neurons into photosensitive cells, bypassing damaged photoreceptors and enabling vision under normal light conditions. This approach addresses a large unmet need, as current treatments are limited. Nanoscope has reported positive preclinical data and early clinical safety signals, positioning it as a potential leader in the optogenetic space. The company is privately held and has not disclosed recent financing or valuation.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 clinical data readout for lead candidate in Retinitis Pigmentosa60% success
• TBDOrphan Drug Designation or Rare Pediatric Disease Designation from FDA80% success
• TBDPartnership or licensing deal with larger ophthalmology or gene therapy company50% success